trending Market Intelligence /marketintelligence/en/news-insights/trending/a9G9KzWAI_HqkunHOGoUOw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

GHO Capital acquires early phase drug developer from Mentha Capital

Street Talk Episode 56 - Latest bank MOE shows even the strong need scale to thrive

South State CenterState MOE Shows Even The Strong Need Scale To Thrive

Talking Bank Stocks, Playing The M&A Trade With Longtime Investor

Report: Kashkari Says Fed In Holding Pattern But Rate Cut Still Possible


GHO Capital acquires early phase drug developer from Mentha Capital

Specialist healthcare investment adviser GHO Capital Partners LLP acquired Ardena Holding NV and its existing management from Amsterdam-based Mentha Capital BV.

Alvarez & Marsal, Deloitte, Sidley Austin LLP, Loyens & Loeff NV, CIL Management Consultants, E&Y’s Life Sciences Corporate Finance Team, Matrix Global Services Ltd., AON, ERM and Saola Healthcare Partners advised GHO on the transaction.

William Blair, Deloitte, LEK Consulting, deBreij, Schoups, Delphi, Ellex, CorporateWise, van Doorne and ERM advised Ardena.

GHO recently announced the close of their second specialist healthcare private equity fund at its hard cap of €975 million and last year completed investments in Sterling Pharma and BioAgilytix, as well as exits from Quotient Sciences and Caprion Biosciences.

Belgium-headquartered Ardena is a multiservice contract development and manufacturing organization focused on early phase drug development.